ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
ADC Therapeutics SA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.44+0.04 (+2.86%)
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.64 (−64.71%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ADC Therapeutics SA grew revenue 3.0% to $79.58M over the twelve months to Jun 30, 2026. Free cash flow was -$102.30M.
Revenue
$79.58M
+3.0% vs. a year earlier
Operating income
-$99.55M
TTM Q2 2026
Free cash flow
-$102.30M
TTM Q2 2026
EPS, diluted
-$0.66
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $223.22M
- P/E ratio
- –
- Price to sales
- 2.80
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -45.83%
Fundamentals
- Revenue
- $79.58M
- Net income
- -$96.91M
- EPS, diluted
- -$0.66
- Free cash flow
- -$102.30M
- Book value per share
- -$1.47
- Diluted shares
- 155M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$79.58M+3.0% YoY
Gross profit
–
Operating income
-$99.55M
Net income
-$96.91M
EPS, diluted
-$0.66
Free cash flow
-$102.30M
Reported periodTrailing twelve months